Xiangchen Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiangchen Gu has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Lin Xie
Department of Nephrology Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine Shanghai China
5 shared publicationsYi Wang
Department of Nephrology Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine Shanghai China
5 shared publications- Jingyuan Xie
Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications Min Chen
Department of Nephrology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
3 shared publicationsWen Du
Department of Nephrology Ruijin Hospital Luwan Branch Shanghai Jiaotong University School of Medicine Shanghai China
3 shared publicationsZhaonan Wei
Department of Nephrology The Second Affiliated Hospital of Soochow University Suzhou China
3 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (26) , e19855
TRAP5 Inhibition Targeting Scar‐Associated Macrophages Ameliorates Acute Kidney Injury to Chronic Kidney Disease Transition
The transition from acute kidney injury (AKI) to chronic kidney disease (CKD) lacks effective therapies. Using a murine aristolochic acid I model (AAI), followed by a 2 week remodeling phase, we mapped macrophage states across the AKI to CKD transition. Single‐cell RNA sequencing of kidneys from control, acute, and remodeling stages profiled 39 345 cells spanning 18 clusters. Macrophage subclustering and trajectories revealed emergence of scar‐associated macrophages (SMs) marked by high Acp5 (encoding tartrate‐resistant acid phosphatase 5 (TRAP5)) and enriched during the remodeling phase. Cell–cell communication highlighted a dominant Spp1–Cd44 axis driving SM activation. Immunofluorescence confirmed TRAP5 + CD68 + macrophage accumulation in multiple murine CKD and human CKD biopsies. Functionally, pharmacological TRAP5 inhibition conferred robust protection against AKI–CKD transition. TRAP5 blockade initiated in the AKI phase markedly attenuated fibrosis, inflammation, and renal dysfunction in both AAI and ischemia‐reperfusion injury (IRI) models; while preinhibition similarly mitigated unilateral ureteral obstruction (UUO)‐induced fibrosis. In bone marrow‐derived macrophages (BMDMs), TRAP5 blockade abrogated osteopontin (Spp1)‐driven metabolic and profibrotic reprogramming. In conclusion, TRAP5 + scar‐associated macrophages are disease‐promoting effectors of maladaptive remodeling in AKI–CKD transition. Targeting TRAP5 not only suppresses profibrotic macrophage activation but also protects renal structure and function across multiple models, establishing TRAP5 inhibition as a promising therapeutic strategy to halt CKD progression.
- 3 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (26) , e19855
Open AccessTRAP5 Inhibition Targeting Scar‐Associated Macrophages Ameliorates Acute Kidney Injury to Chronic Kidney Disease Transition
The transition from acute kidney injury (AKI) to chronic kidney disease (CKD) lacks effective therapies. Using a murine aristolochic acid I model (AAI), followed by a 2 week remodeling phase, we mapped macrophage states across the AKI to CKD transition. Single‐cell RNA sequencing of kidneys from control, acute, and remodeling stages profiled 39 345 cells spanning 18 clusters. Macrophage subclustering and trajectories revealed emergence of scar‐associated macrophages (SMs) marked by high Acp5 (encoding tartrate‐resistant acid phosphatase 5 (TRAP5)) and enriched during the remodeling phase. Cell–cell communication highlighted a dominant Spp1–Cd44 axis driving SM activation. Immunofluorescence confirmed TRAP5 + CD68 + macrophage accumulation in multiple murine CKD and human CKD biopsies. Functionally, pharmacological TRAP5 inhibition conferred robust protection against AKI–CKD transition. TRAP5 blockade initiated in the AKI phase markedly attenuated fibrosis, inflammation, and renal dysfunction in both AAI and ischemia‐reperfusion injury (IRI) models; while preinhibition similarly mitigated unilateral ureteral obstruction (UUO)‐induced fibrosis. In bone marrow‐derived macrophages (BMDMs), TRAP5 blockade abrogated osteopontin (Spp1)‐driven metabolic and profibrotic reprogramming. In conclusion, TRAP5 + scar‐associated macrophages are disease‐promoting effectors of maladaptive remodeling in AKI–CKD transition. Targeting TRAP5 not only suppresses profibrotic macrophage activation but also protects renal structure and function across multiple models, establishing TRAP5 inhibition as a promising therapeutic strategy to halt CKD progression.
- Open Access
- 7 January 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (5) , 969-981
Dapagliflozin Reduces Kidney Inflammation in Alport Syndrome by Inhibiting the Stimulator of IFN Genes Pathway in Renal Tubular Epithelial Cells
Key Points: Dapagliflozin reduces proteinuria in patients with Alport syndrome. Dapagliflozin plays an anti-inflammatory role by inhibiting the stimulator of IFN genes pathway in tubular epithelial cells of Alport syndrome mice. Background: Alport syndrome (AS) is a hereditary kidney disease caused by COL4A3/4/5 mutations that lack of effective treatments. Sodium-glucose cotransporter 2 inhibitors have demonstrated renal and cardiovascular protective effects in patients with CKD; however, their long-term effects in patients with AS and the underlying mechanisms remain to be clarified. Methods: We conducted a single-arm, prospective study to examine the effect of dapagliflozin in patients with AS. In parallel, Col4a3 p.C1615Y-mutant mice (129S2/Sv background) were used as an AS model to investigate the renoprotective mechanisms of dapagliflozin. Results: A total of twenty-one patients with AS were enrolled. After approximately 12 months of follow-up (12.6±1.2 months), the mean 24-hour urinary protein decreased by 29% to 1.25±0.73 g from baseline (1.75±0.90; P < 0.001). The eGFR showed no significant difference compared with baseline (76±28 versus 77±29 ml/min per 1.73 m 2 , P = 0.57). In the animal studies, dapagliflozin significantly reduced macrophage infiltration and the expression of inflammatory cytokines levels in the renal cortex of Col4a3 -mutant mice. Mechanistic studies showed that stimulator of IFN genes (STING) pathway was activated in the renal cortex and tubular epithelial cells (TECs) from Col4a3 mice, contributing to a proinflammatory phenotype. Dapagliflozin effectively inhibited STING activation and suppressed inflammatory cytokines production in mutant TECs. Conclusions: Dapagliflozin can reduce proteinuria in patients with AS and plays an anti-inflammatory role by inhibiting the STING pathway in TECs of AS mice.
- 7 January 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (5) , 969-981
Open AccessDapagliflozin Reduces Kidney Inflammation in Alport Syndrome by Inhibiting the Stimulator of IFN Genes Pathway in Renal Tubular Epithelial Cells
Key Points: Dapagliflozin reduces proteinuria in patients with Alport syndrome. Dapagliflozin plays an anti-inflammatory role by inhibiting the stimulator of IFN genes pathway in tubular epithelial cells of Alport syndrome mice. Background: Alport syndrome (AS) is a hereditary kidney disease caused by COL4A3/4/5 mutations that lack of effective treatments. Sodium-glucose cotransporter 2 inhibitors have demonstrated renal and cardiovascular protective effects in patients with CKD; however, their long-term effects in patients with AS and the underlying mechanisms remain to be clarified. Methods: We conducted a single-arm, prospective study to examine the effect of dapagliflozin in patients with AS. In parallel, Col4a3 p.C1615Y-mutant mice (129S2/Sv background) were used as an AS model to investigate the renoprotective mechanisms of dapagliflozin. Results: A total of twenty-one patients with AS were enrolled. After approximately 12 months of follow-up (12.6±1.2 months), the mean 24-hour urinary protein decreased by 29% to 1.25±0.73 g from baseline (1.75±0.90; P < 0.001). The eGFR showed no significant difference compared with baseline (76±28 versus 77±29 ml/min per 1.73 m 2 , P = 0.57). In the animal studies, dapagliflozin significantly reduced macrophage infiltration and the expression of inflammatory cytokines levels in the renal cortex of Col4a3 -mutant mice. Mechanistic studies showed that stimulator of IFN genes (STING) pathway was activated in the renal cortex and tubular epithelial cells (TECs) from Col4a3 mice, contributing to a proinflammatory phenotype. Dapagliflozin effectively inhibited STING activation and suppressed inflammatory cytokines production in mutant TECs. Conclusions: Dapagliflozin can reduce proteinuria in patients with AS and plays an anti-inflammatory role by inhibiting the STING pathway in TECs of AS mice.
- 23 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (795) , eadn3079
Glutathione-specific gamma–glutamylcyclotransferase 1 ( CHAC1 ) increases kidney disease risk by modulating ferroptosis
Genome-wide association studies (GWASs) have identified more than 1000 loci where genetic variants correlate with kidney function. However, the specific genes, cell types, and mechanisms influenced by these genetic variants remain largely uncharted. Here, we identified glutathione-specific gamma–glutamylcyclotransferase 1 ( CHAC1 ) on chromosome 15 as affected by GWAS variants by analyzing human kidney gene expression and methylation information. Both CHAC1 RNA and protein were expressed in the loop of Henle region in mouse and human kidneys, and CHAC1 expression was higher in patients carrying disease risk variants. Using CRISPR technology, we created mice with a single functional copy of the Chac1 gene ( Chac1 +/− ) that displayed no baseline phenotypic alterations in kidney structure or function. These mice demonstrated resilience to kidney disease in multiple models, including folic acid–induced nephropathy, adenine-induced chronic kidney disease, and uninephrectomy-streptozotocin–induced diabetic nephropathy. We further showed that CHAC1 plays a critical role in degrading the cellular antioxidant glutathione. Tubule cells isolated from Chac1 +/− mice showed increased glutathione, decreased lipid peroxidation, improved cell viability, and protection against ferroptosis. Expression of ferroptosis-associated genes was also lower in mice with only one copy of Chac1 . Higher CHAC1 protein also correlated with ferroptosis-related protein abundance in kidney biopsies from patients with kidney disease. This study positions CHAC1 as an important mediator of kidney disease that influences glutathione concentrations and ferroptosis, suggesting potential avenues to explore for the treatment of kidney diseases.
- 23 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (795) , eadn3079
Glutathione-specific gamma–glutamylcyclotransferase 1 ( CHAC1 ) increases kidney disease risk by modulating ferroptosis
Genome-wide association studies (GWASs) have identified more than 1000 loci where genetic variants correlate with kidney function. However, the specific genes, cell types, and mechanisms influenced by these genetic variants remain largely uncharted. Here, we identified glutathione-specific gamma–glutamylcyclotransferase 1 ( CHAC1 ) on chromosome 15 as affected by GWAS variants by analyzing human kidney gene expression and methylation information. Both CHAC1 RNA and protein were expressed in the loop of Henle region in mouse and human kidneys, and CHAC1 expression was higher in patients carrying disease risk variants. Using CRISPR technology, we created mice with a single functional copy of the Chac1 gene ( Chac1 +/− ) that displayed no baseline phenotypic alterations in kidney structure or function. These mice demonstrated resilience to kidney disease in multiple models, including folic acid–induced nephropathy, adenine-induced chronic kidney disease, and uninephrectomy-streptozotocin–induced diabetic nephropathy. We further showed that CHAC1 plays a critical role in degrading the cellular antioxidant glutathione. Tubule cells isolated from Chac1 +/− mice showed increased glutathione, decreased lipid peroxidation, improved cell viability, and protection against ferroptosis. Expression of ferroptosis-associated genes was also lower in mice with only one copy of Chac1 . Higher CHAC1 protein also correlated with ferroptosis-related protein abundance in kidney biopsies from patients with kidney disease. This study positions CHAC1 as an important mediator of kidney disease that influences glutathione concentrations and ferroptosis, suggesting potential avenues to explore for the treatment of kidney diseases.
- Open Access
- 23 October 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-14
C/EBPα-mediated ACSL4-dependent ferroptosis exacerbates tubular injury in diabetic kidney disease
Diabetic kidney disease (DKD) is a prevalent and debilitating complication of diabetes characterized by progressive renal function decline and a lack of effective treatment options. Here, we investigated the role of the transcription factor CCAAT/enhancer binding protein alpha (C/EBPα) in DKD pathogenesis. Analysis of renal biopsy samples revealed increased C/EBPα expression in patients with DKD. Using RNA sequencing and proteomics, we explored the mechanisms through which the C/EBPα contributes to DKD. Our findings demonstrated that C/EBPα exacerbated tubular injury by promoting acyl-CoA synthetase long-chain family member 4 (ACSL4)-dependent ferroptosis. We identified that C/EBPα upregulated ACSL4 expression by binding to its transcription regulatory sequence (TRS), leading to elevated lipid peroxidation and ferroptosis. Furthermore, inhibition or genetic ablation of C/EBPα attenuated ferroptosis and mitigated tubular injury in DKD. These results highlighted the C/EBPα-ACSL4-ferroptosis pathway as a promising therapeutic target for DKD treatment.
- 23 October 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-14
Open AccessC/EBPα-mediated ACSL4-dependent ferroptosis exacerbates tubular injury in diabetic kidney disease
Diabetic kidney disease (DKD) is a prevalent and debilitating complication of diabetes characterized by progressive renal function decline and a lack of effective treatment options. Here, we investigated the role of the transcription factor CCAAT/enhancer binding protein alpha (C/EBPα) in DKD pathogenesis. Analysis of renal biopsy samples revealed increased C/EBPα expression in patients with DKD. Using RNA sequencing and proteomics, we explored the mechanisms through which the C/EBPα contributes to DKD. Our findings demonstrated that C/EBPα exacerbated tubular injury by promoting acyl-CoA synthetase long-chain family member 4 (ACSL4)-dependent ferroptosis. We identified that C/EBPα upregulated ACSL4 expression by binding to its transcription regulatory sequence (TRS), leading to elevated lipid peroxidation and ferroptosis. Furthermore, inhibition or genetic ablation of C/EBPα attenuated ferroptosis and mitigated tubular injury in DKD. These results highlighted the C/EBPα-ACSL4-ferroptosis pathway as a promising therapeutic target for DKD treatment.
- Open Access
- 21 May 2024
- Published by Elsevier in Kidney International
- Vol. 106 (3) , 433-449
Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation
- 21 May 2024
- Published by Elsevier in Kidney International
- Vol. 106 (3) , 433-449
Open AccessTauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation
- Open Access
- 1 April 2024
- Published by Walter de Gruyter GmbH in Journal of Translational Internal Medicine
- Vol. 12 (2) , 129-133
Progress in therapeutic targets on podocyte for Alport syndrome
Article Progress in therapeutic targets on podocyte for Alport syndrome was published on April 1, 2024 in the journal Journal of Translational Internal Medicine (volume 12, issue 2).
- 1 April 2024
- Published by Walter de Gruyter GmbH in Journal of Translational Internal Medicine
- Vol. 12 (2) , 129-133
Open AccessProgress in therapeutic targets on podocyte for Alport syndrome
Article Progress in therapeutic targets on podocyte for Alport syndrome was published on April 1, 2024 in the journal Journal of Translational Internal Medicine (volume 12, issue 2).
- Open Access
- 12 December 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (12) , 1-17
Activation of GPER1 in macrophages ameliorates UUO-induced renal fibrosis
Numerous studies have proven the critical role of macrophages in the renal fibrosis process. Notably, G Protein-coupled Estrogen Receptor 1 (GPER1), a novel estrogen receptor, has been shown to play a ubiquitous role in regulating macrophage activities and proinflammatory pathways. However, the precise role of GPER1 in macrophage-mediated renal fibrosis is unknown. In this study, we aimed to investigate the function of macrophage GPER1 in the UUO-induced renal fibrosis model. Compared to vehicle-treated ovariectomized (OVX) female and male unilateral ureteral obstruction (UUO) models, we observed that G-1 (GPER1 agonist)-treated OVX female and male UUO mice had fewer renal fibrotic lesions and less M1 and M2 macrophage infiltration in the kidney tissues. Conversely, Gper1 deletion in male UUO mice accelerated renal fibrosis and increased inflammation. In vitro studies also revealed that GPER1 activation reduced M0 macrophage polarization towards M1 or M2 phenotypes. The RNA-sequencing analysis and immunoblotting indicated that GPER1 activation was primarily involved in downregulating immune pathways activation and inactivating MAPK pathways. Tubular epithelial cells co-cultured with G-1-pretreated M1 macrophages exhibited fewer injuries and immune activation. In addition, fibroblasts co-cultured with G-1-pretreated M2 macrophages showed downregulated extracellular matrix expression. Overall, this is the first study to demonstrate the effect of GPER1 on macrophage-mediated renal fibrosis via inhibition of M1 and M2 macrophage activation. These findings indicate that GPER1 may be a promising therapeutic target for treating renal fibrosis.
- 12 December 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (12) , 1-17
Open AccessActivation of GPER1 in macrophages ameliorates UUO-induced renal fibrosis
Numerous studies have proven the critical role of macrophages in the renal fibrosis process. Notably, G Protein-coupled Estrogen Receptor 1 (GPER1), a novel estrogen receptor, has been shown to play a ubiquitous role in regulating macrophage activities and proinflammatory pathways. However, the precise role of GPER1 in macrophage-mediated renal fibrosis is unknown. In this study, we aimed to investigate the function of macrophage GPER1 in the UUO-induced renal fibrosis model. Compared to vehicle-treated ovariectomized (OVX) female and male unilateral ureteral obstruction (UUO) models, we observed that G-1 (GPER1 agonist)-treated OVX female and male UUO mice had fewer renal fibrotic lesions and less M1 and M2 macrophage infiltration in the kidney tissues. Conversely, Gper1 deletion in male UUO mice accelerated renal fibrosis and increased inflammation. In vitro studies also revealed that GPER1 activation reduced M0 macrophage polarization towards M1 or M2 phenotypes. The RNA-sequencing analysis and immunoblotting indicated that GPER1 activation was primarily involved in downregulating immune pathways activation and inactivating MAPK pathways. Tubular epithelial cells co-cultured with G-1-pretreated M1 macrophages exhibited fewer injuries and immune activation. In addition, fibroblasts co-cultured with G-1-pretreated M2 macrophages showed downregulated extracellular matrix expression. Overall, this is the first study to demonstrate the effect of GPER1 on macrophage-mediated renal fibrosis via inhibition of M1 and M2 macrophage activation. These findings indicate that GPER1 may be a promising therapeutic target for treating renal fibrosis.
- Open Access
- 7 December 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1286649
Myelodysplastic syndrome-like response after voriconazole treatment of systemic lupus erythematosus complicated with fungal infection: a case report
Background: Voriconazole is mainly used to treat progressive and potentially life-threatening infections in immunocompromised patients. The adverse drug reactions related to voriconazole are varied. In some rare cases, the use of voriconazole can result in myelodysplastic syndrome (MDS)-like adverse reactions.Case presentation: Here, we present a rare case of systemic lupus erythematosus patient with a fungal infection that developed MDS-like adverse reactions after treatment with voriconazole. The patient was admitted to the hospital because of 3 days of chest tightness and dyspnea. After the admission, the patient’s sputum culture showed Candida albicans infection, and voriconazole was prescribed to be taken orally. After using voriconazole, drug-related adverse reactions such as visual impairment, nausea, vomiting, hiccup, middle and lower abdominal pain, disorders of consciousness, delirium, hallucination, slow response, and subcutaneous ecchymosis appeared, as well as the gradually increased serum creatinine, oliguria, and aggravated lower limb edema. In addition, there was a decrease in peripheral blood cells, and MDS-like changes in bone marrow were indicated by bone marrow biopsy. After discontinuing voriconazole, drug-related adverse symptoms disappeared, and hematocytopenia and the changes in MDS were significantly improved, which was confirmed by a subsequent bone marrow puncture at a 6 months interval.Conclusion: This case reminded us that when using voriconazole for treatment, individual differences in patients should be considered, and the blood concentration of voriconazole should be closely monitored. Otherwise, potential drugs that affect voriconazole metabolism should be noted, and related adverse symptoms of patients should be closely observed during medication to reduce the occurrence of adverse drug events.
- 7 December 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1286649
Open AccessMyelodysplastic syndrome-like response after voriconazole treatment of systemic lupus erythematosus complicated with fungal infection: a case report
Background: Voriconazole is mainly used to treat progressive and potentially life-threatening infections in immunocompromised patients. The adverse drug reactions related to voriconazole are varied. In some rare cases, the use of voriconazole can result in myelodysplastic syndrome (MDS)-like adverse reactions.Case presentation: Here, we present a rare case of systemic lupus erythematosus patient with a fungal infection that developed MDS-like adverse reactions after treatment with voriconazole. The patient was admitted to the hospital because of 3 days of chest tightness and dyspnea. After the admission, the patient’s sputum culture showed Candida albicans infection, and voriconazole was prescribed to be taken orally. After using voriconazole, drug-related adverse reactions such as visual impairment, nausea, vomiting, hiccup, middle and lower abdominal pain, disorders of consciousness, delirium, hallucination, slow response, and subcutaneous ecchymosis appeared, as well as the gradually increased serum creatinine, oliguria, and aggravated lower limb edema. In addition, there was a decrease in peripheral blood cells, and MDS-like changes in bone marrow were indicated by bone marrow biopsy. After discontinuing voriconazole, drug-related adverse symptoms disappeared, and hematocytopenia and the changes in MDS were significantly improved, which was confirmed by a subsequent bone marrow puncture at a 6 months interval.Conclusion: This case reminded us that when using voriconazole for treatment, individual differences in patients should be considered, and the blood concentration of voriconazole should be closely monitored. Otherwise, potential drugs that affect voriconazole metabolism should be noted, and related adverse symptoms of patients should be closely observed during medication to reduce the occurrence of adverse drug events.
- Open Access
- 20 September 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1235716
Emerging roles of proximal tubular endocytosis in renal fibrosis
Endocytosis is a crucial component of many pathological conditions. The proximal tubules are responsible for reabsorbing the majority of filtered water and glucose, as well as all the proteins filtered through the glomerular barrier via endocytosis, indicating an essential role in kidney diseases. Genetic mutations or acquired insults could affect the proximal tubule endocytosis processes, by disturbing or overstressing the endolysosomal system and subsequently activating different pathways, orchestrating renal fibrosis. This paper will review recent studies on proximal tubular endocytosis affected by other diseases and factors. Endocytosis plays a vital role in the development of renal fibrosis, and renal fibrosis could also, in turn, affect tubular endocytosis.
- 20 September 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1235716
Open AccessEmerging roles of proximal tubular endocytosis in renal fibrosis
Endocytosis is a crucial component of many pathological conditions. The proximal tubules are responsible for reabsorbing the majority of filtered water and glucose, as well as all the proteins filtered through the glomerular barrier via endocytosis, indicating an essential role in kidney diseases. Genetic mutations or acquired insults could affect the proximal tubule endocytosis processes, by disturbing or overstressing the endolysosomal system and subsequently activating different pathways, orchestrating renal fibrosis. This paper will review recent studies on proximal tubular endocytosis affected by other diseases and factors. Endocytosis plays a vital role in the development of renal fibrosis, and renal fibrosis could also, in turn, affect tubular endocytosis.
- 1 January 2022
- Vol. 14 (3) , 1567-1577
Icariin attenuates renal interstitial fibrosis through G protein-coupled estrogen receptor in a UUO murine model
Background/Aims: Icariin plays an antifibrotic role in the unilateral ureteral obstruction (UUO) model; however, its primary mechanism has not been elucidated. G protein-coupled estrogen receptor (GPER) has been shown to be associated with fibrosis and mitochondrial biogenesis. In this study, we aimed to investigate the impact of GPER on renal fibrosis and whether icariin attenuates renal fibrosis dependent on GPER. Methods: In the in vivo study, 10-week-old mice were subjected to the UUO model followed by UUO with icariin, G-15 (a GPER antagonist), and icariin + G-15. GPER expression, renal fibrosis levels, and mitochondrial alterations were measured and analyzed. In an in vitro study, we examined the antifibrotic effect of icariin on rat renal fibroblasts (NRK-49F) via GPER. Results: Consistent with a previous study, icariin significantly attenuated fibrotic markers and protected the kidneys against mitochondrial injuries in the UUO model. However, G-15 exacerbated renal fibrosis and abolished the protective effect of icariin in the UUO model. Furthermore, antagonizing or knocking down GPER in NRK-49F significantly increased fibrotic markers and eliminated the antifibrotic effect of icariin. Conclusions: Our findings indicate that (1) GPER inhibition exacerbates renal fibrosis, and (2) icariin exerts antifibrotic effects against renal fibrosis through GPER.
- 1 January 2022
- Vol. 14 (3) , 1567-1577
Icariin attenuates renal interstitial fibrosis through G protein-coupled estrogen receptor in a UUO murine model
Background/Aims: Icariin plays an antifibrotic role in the unilateral ureteral obstruction (UUO) model; however, its primary mechanism has not been elucidated. G protein-coupled estrogen receptor (GPER) has been shown to be associated with fibrosis and mitochondrial biogenesis. In this study, we aimed to investigate the impact of GPER on renal fibrosis and whether icariin attenuates renal fibrosis dependent on GPER. Methods: In the in vivo study, 10-week-old mice were subjected to the UUO model followed by UUO with icariin, G-15 (a GPER antagonist), and icariin + G-15. GPER expression, renal fibrosis levels, and mitochondrial alterations were measured and analyzed. In an in vitro study, we examined the antifibrotic effect of icariin on rat renal fibroblasts (NRK-49F) via GPER. Results: Consistent with a previous study, icariin significantly attenuated fibrotic markers and protected the kidneys against mitochondrial injuries in the UUO model. However, G-15 exacerbated renal fibrosis and abolished the protective effect of icariin in the UUO model. Furthermore, antagonizing or knocking down GPER in NRK-49F significantly increased fibrotic markers and eliminated the antifibrotic effect of icariin. Conclusions: Our findings indicate that (1) GPER inhibition exacerbates renal fibrosis, and (2) icariin exerts antifibrotic effects against renal fibrosis through GPER.